Dengue fever, an infectious tropical disease caused by a mosquito-borne virus, afflicts millions of people each year, causing fever, headache, muscle and joint pains and a characteristic skin rash, researchers said.
In some people the disease progresses to a severe, often fatal, form known as dengue hemorrhagic fever.
Despite its heavy toll, the prevention and clinical treatment of dengue infection has been a "dramatic failure in public health compared to other infectious diseases like HIV," said Ping Liu of the University of North Carolina at Chapel Hill.
Liu along with dengue fever expert Aravinda de Silva, used high-resolution microscopes to examine the expression of a particular protein, known as DC-SIGN, on the surface of immune system cells called dendritic cells.
The normal role of DC-SIGN (dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin) is to capture pathogens so that fragments of those pathogens can be presented as antigens on the surface of the dendritic cells.
Such antigens then are recognised by T cells - the workhorse cells of the immune system - "which is one of the first steps in the normal immune response," Liu said.
"DC-SIGN has a unique carbohydrate recognition domain on its extracellular portion, which binds to all sorts of carbohydrates on pathogens," she said.
"An effective medication or vaccine should stop the process of dengue virus entry into cells," Liu said.
She said, de Silva and his colleagues have identified strong neutralisation antibodies that block dengue infection.
By identifying the mechanism of antibody neutralisation, Liu and colleagues hope to advance the development of vaccines for dengue virus infections.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
